Bloomios Past Earnings Performance
Past criteria checks 0/6
Bloomios's earnings have been declining at an average annual rate of -582.4%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 46.5% per year.
Key information
-582.4%
Earnings growth rate
-294.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 46.5% |
| Return on equity | n/a |
| Net Margin | -481.3% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Bloomios makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 8 | -40 | 7 | 0 |
| 30 Jun 23 | 9 | -16 | 7 | 0 |
| 31 Mar 23 | 7 | -15 | 7 | 0 |
| 31 Dec 22 | 6 | -14 | 6 | 0 |
| 30 Sep 22 | 6 | -6 | 6 | 0 |
| 30 Jun 22 | 7 | -3 | 5 | 0 |
| 31 Mar 22 | 8 | -2 | 5 | 0 |
| 31 Dec 21 | 8 | -2 | 4 | 0 |
| 30 Sep 21 | 8 | -2 | 4 | 0 |
| 30 Jun 21 | 6 | -2 | 3 | 0 |
| 31 Mar 21 | 3 | -3 | 2 | 0 |
| 31 Dec 20 | 1 | -1 | 1 | 0 |
| 31 Oct 20 | 0 | 0 | 0 | 0 |
| 31 Jul 20 | 0 | 0 | 0 | 0 |
| 30 Apr 20 | 0 | 0 | 0 | 0 |
| 31 Jan 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
| 31 Oct 19 | 0 | 0 | 0 | 0 |
Quality Earnings: BLMS is currently unprofitable.
Growing Profit Margin: BLMS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BLMS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BLMS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLMS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: BLMS's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.